Effects of systemic meglumine antimoniate on ECG in patients with cutaneous leishmaniasis
Keywords:
Cutaneous Leishmaniasis, meglumine antimoniate, sinus bradycardia, ECGAbstract
Background: Cutaneous Leishmaniasis (CL) is widespread in tropical and subtropical regions, particularly in low-income groups with poor sanitation. It produces mild to severe disfiguring skin lesions that grow over weeks to months. The rate of spontaneous cure is minimal. The gold standard treatment for cutaneous leishmaniasis is meglumine antimoniate. Headaches, myalgias, fever, fatigue, urticarial reactions, gastrointestinal issues, and EKG changes are all common side effects of systemic glucantime® therapy. Methods: Objective: To determine ECG changes in cutaneous leishmaniasis patients, treated with systemic meglumine antimoniate therapy in Khyber Teaching Hospital. Study design: Descriptive case series.Setting: Department of Dermatology, Khyber Teaching Hospital Peshawar.Duration of study: Minimum six months i.e., March 25, 2021 to September 25, 2021. Material and methods: All patients with cutaneous leshmaniasis who met the inclusion criteria and were using systemic melglumine antimoniate (IM) were evaluated after receiving ethical approval from the hospital ethical committee. All patients signed a written informed consent form, and a thorough general physical, systemic, and dermatological examination was performed. Before and after twenty-one days of treatment with sysetmic glucantime® at a dose of 20 mg per kilogram body weight, all patients had their ECGs and related investigations such as liver and renal function tests. To exclude any bias from the study, strict exclusion criteria were used. Results: The majority of the 87 patients were men (55.2%). The prevalence of ECG abnormalities (effect) was 24%. Sinus bradycardia (33.3%) was the most common ECG changes, while ST segment elevation was the least common (4.8%). Gender (p=0.76), age (p=0.15), and CL duration (p <0.001) were used to stratify the frequency of ECG changes (effect). Conclusion: ECG alterations have been linked to the use of Glucantime® systemically. As a result, during the drug's systemic administration, careful monitoring is required.References
Saheki MN, Lyra MR, Bedoya-Pacheco SJ, Antônio LD, Pimentel MI, Salgueiro MD et al. Low versus high dose of antimony for American cutaneous leishmaniasis. PloS One. 2017;12(5):e0178592.
Tareen A, Ahmad SA, Khan I. Comparison of the efficacy of Intralesional versus intramuscular injection Meglumine Antimoniate in the treatment of sores of cutaneous leishmaniasis. Int J Pathol. 2018;14(5):118-22.
Nafari A, Cheraghipour K, Sepahvand M, Shahrokhi G, Gabal E, Mahmoudvand H. Nanoparticles: New agents toward treatment of leishmaniasis. Parasite Epidemiol Control. 2020:e00156.
Gonçalves SV, Costa CH. Treatment of cutaneous leishmaniasis with thermotherapy in Brazil. An Bras Dermatol. 2018;93(3):347-55.
Piccolo Johanning L, Pérez Elizondo E, Álvarez Morales L, Wang Zúñiga C, Sancho Torres M. Leishmaniasis: Therapeutic options in the pediatric population. Legal Med Costa Rica. 2018;35(1):52-64.
Nassif PW, De Mello TF, Navasconi TR, Mota CA, Demarchi IG, Aristides SM, et al. Safety and efficacy of current alternatives in the topical treatment of cutaneous leishmaniasis: a systematic review. Parasitol. 2017;144(8):995.
Ramalho DB, Silva RE, Senna MC, Moreira HS, Pedras MJ, Avelar DM, et al. Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis. Mem Inst Oswaldo Cruz. 2018;113(9):e180200.
Blum J, Neumayr A, Lockwood D. Treatment of tegumentary forms of leishmaniasis in the leishmaniases. Springer 2018. p191-225.
Taheri AR, Sabouri Rad S, Molkara S. Systemic Treatments of leishmaniasis. Rev Clin Med. 2019;6(3):91-7.
Arcos L, Rincón C, Vanegas D, Medina R. Electrical storm and torsade de pointes associated with antimonial treatment in a patient with cutaneous leishmaniasis. Rev Colomb Entomol. 2018;25(4):279.
de Freitas PF, Borges RR, Leal BH, Gonçalves MN, da Silva AM, Moura FJ et al. Electrocardiogram assessment of patients with American cutaneous leishmaniasis treated with pentavalent antimonial Glucantime®. J Trop Pathol. 2014;43(4):405-11.
Verde M, Yzuel A, Riera C, Fisa R, Alcover M, Fernández A. Leishmaniosis caused by leishmania infantum in ferrets: Update review. Vet Anim Sci. 2021;15:100229.
Eskandari SE, Khamesipour A, Jaafari MR, Javadi A, Mohammadi AM, Valian HK, et al. Combination of topical liposomal amphotericin B and Glucantime in comparison with glucantime alone for the treatment of anthroponotic cutaneous leishmaniasis (ACL) caused by leishmania tropica: study protocol for a randomized, controlled trial. Iran J Microbiol. 2021;13(5):718-23.
Zorbozan O, Evren V, Harman M, Özbilgin A, Alkan Yılmaz Ö, Turgay N. Evaluating the Glucantime Concentration for the ex vivo Glial Cell Model of Antimony- resistant leishmania tropica Amastigotes. Turkiye Parazitol Derg. 2021;45(4):237-40.
Seif MA, Al-mohammed HI. Assessment of the oxidative and nitrosative stress in the serum of saudi patients with cutaneous leishmaniasis before and after treatment. J Parasitol. 2021;107(5):810-16.
Duque L, López HG, Naranjo S, Aristizábal JM, Duque M. Glucantime and QTc interval prolongation: A fatal combination. CES Med. 2019;33(3):201-7.
Tahir M, Bashir U, Ahmed N, Mumtaz J. Electrocardiographic changes with standard dose of meglumine antimoniate therapy in cutaneous leishmaniasis. Pak Armed Forces Med J. 2021;71(4):1235-38.
Shanehsaz SM, Ishkhanian S. Electrocardiographic and biochemical adverse effects of meglumine antimoniate (MA) during treatment of Syrian cutaneous leishmaniasis patients. J Pak Assoc Dermatol. 2013;23(4):412-7.
Abid R, Haleem S, Ghani S, Ahmed N, Farman M, Bukhari M, et al. Electrocardiographic changes during treatment with cutaneous leishmaniasis. Pak Heart J. 2013;46(1):51-6.
Daadaa N, Youssef S, Haggui A, Harbaoui S, Jaber K, Doss N, et al. New onset of sinoatrial block in a young patient treated with systemic meglumine antimoniate. Clin Case Rep. 2021;9(3):1797-8.
